Life Biosciences Announces First-in-Human Data from Ongoing Phase 1 Trial Evaluating ER-100 in Optic Neuropathies
Life Biosciences reported positive interim Phase 1 clinical trial data for its drug candidate ER-100, which is being tested for the treatment of open-angle glaucoma. The drug was well-tolerated by participants and showed early signs of visual field improvement.
Why it matters
This represents a potential breakthrough in treating age-related vision loss, which is currently considered irreversible.
Administration of ER-100 was well-tolerated through Day 56 in three participants with glaucoma, supporting dose escalation in the ongoing trial
BOSTON, Oct. 08, 2026 (GLOBE NEWSWIRE) -- Life Biosciences ("Life Bio”), a biotechnology company pioneering cellular rejuvenation medicines to reverse diseases of aging, today announced interim data from its Phase 1 clinical trial of ER-100 in three participants with open angle glaucoma (OAG). The data demonstrated that a single intravitreal administration along with daily oral doxycycline was well-tolerated through Day 56 in all three participants and showed preliminary signals of improvement in visual field testing in two participants.
Get smarter about the news
Sign up free for a feed built around what you actually care about, Dive Deeper research on any story, and the full text of every article.
Create free accountAlready have an account? Sign in